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Expression of the HGF receptor c-met by macrophages in
experimental autoimmune encephalomyelitis
Abstract
Hepatocyte growth factor (HGF) is a pleiotropic cytokine able to evoke a wide array of cellular
responses including proliferation, migration, and survival through activation of its receptor c-met.
Various types of leukocytes have been described to express c-met suggesting that HGF/c-met signaling
may directly influence leukocyte responses in inflammation. We have investigated the HGF/c-met
pathway in experimental autoimmune encephalomyelitis (EAE), a common mouse model of multiple
sclerosis (MS), in which macrophages play a dual role, contributing directly to CNS damage at disease
onset but promoting recovery during remission by removing myelin debris. Here we show that during
EAE both HGF and c-met are expressed in the CNS and that c-met is activated. We subsequently
demonstrate that c-met is primarily expressed in inflammatory lesions by macrophages and a small
number of dendritic cells (DCs) and oligodendrocyte progenitor cells (OPCs) but not by microglia or T
cells. Complementary in vitro experiments show that only LPS and TNFalpha, but not IL-6, IL-10, or
IL-13, are able to induce c-met expression in macrophages. In addition, using TNF signaling deficient
macrophages we demonstrate that LPS and TNFalpha induce c-met through distinct pathways.
Furthermore, TNFalpha- and LPS-induced c-met is functional because treatment of macrophages with
recombinant HGF results in rapid phosphorylation of c-met. Interestingly, HGF/c-met signaling does not
modulate cytokine expression, phagocytosis, or antigen presentation but promotes proliferation of
activated macrophages. Taken together, our data indicate a pro-inflammatory role for the HGF/c-met
pathway in EAE rather than a role in the initiation of repair mechanisms. (c) 2009 Wiley-Liss, Inc.
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ABSTRACT 
Hepatocyte growth factor (HGF) is a pleiotropic cytokine able to evoke a wide array 
of cellular responses including proliferation, migration, and survival through 
activation of its receptor c-met. Various types of leukocytes have been described to 
express c-met suggesting that HGF/c-met signaling may directly influence leukocyte 
responses in inflammation. We have investigated the HGF/c-met pathway in 
experimental autoimmune encephalomyelitis (EAE), a commonly used mouse model 
of multiple sclerosis (MS), in which macrophages play a dual role, contributing 
directly to CNS damage at disease onset but promoting recovery during remission by 
removing myelin debris. 
Here we show that during EAE both HGF and c-met are expressed in the CNS and 
that c-met is activated. We subsequently demonstrate that c-met is primarily 
expressed in inflammatory lesions by macrophages and a small number of dendritic 
cells (DCs) and oligodendrocyte progenitor cells (OPCs) but not by microglia or T 
cells. Complementary in vitro experiments show that only LPS and TNFα, but not IL-
6, IL-10 or IL-13, are able to induce c-met expression in macrophages. In addition, 
using TNF signaling deficient macrophages we demonstrate that LPS and TNFα 
induce c-met through distinct pathways. Furthermore, TNFα- and LPS-induced c-met 
is functional because treatment of macrophages with recombinant HGF results in 
rapid phosphorylation of c-met. Interestingly, HGF/c-met signaling does not modulate 
cytokine expression, phagocytosis or antigen presentation but promotes proliferation 
of activated macrophages. Taken together, our data indicate a pro-inflammatory role 
for the HGF/c-met pathway in EAE rather than a role in the initiation of repair 
mechanisms. 
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INTRODUCTION 
Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS associated with 
demyelination, inflammation and axonal loss (Franklin and Ffrench-Constant 2008; 
Hemmer et al. 2002; Wekerle 2008). The main inflammatory effector cells are CD4+ 
T cells (Bynoe et al. 2007; Platten and Steinman 2005; Wekerle 2008), which are 
initially primed in peripheral lymphoid tissues mainly by antigen presenting dendritic 
cells (DCs). An additional local T cell re-activation phase mediated by CNS-
associated antigen presenting cells (APCs), such as microglia, macrophages and DCs, 
is thought to be essential for the disease to develop (Becher et al. 2006; Platten and 
Steinman 2005). In addition activated microglia and CNS-infiltrating peripheral 
macrophages contribute directly to CNS damage through the production of pro-
inflammatory cytokines, matrix metalloproteinases, glutamate, and free radicals 
(Hemmer et al. 2002; Piani et al. 1991; Piani et al. 1992; Platten and Steinman 2005). 
Important mediators of the cellular inflammatory response during the initiation and 
peak phase of the disease are pro-inflammatory cytokines such as TNFα, IFNγ and 
IL-17, whereas recovery from EAE is initiated by a shift to anti-inflammatory 
cytokines such as IL-4, IL-10 and TGFβ (Hemmer et al. 2002; Platten and Steinman 
2005). During the remission phase of MS, macrophages and microglia are thought to 
play a more beneficial role by removing cellular and myelin debris, a process 
essential for remyelination to occur because myelin debris inhibits oligodendrocyte 
progenitor cell (OPC) migration and differentiation (Franklin 2002; Franklin and 
Ffrench-Constant 2008).  
Hepatocyte growth factor (HGF), also known as scatter factor, was discovered by 
virtue of its growth inducing properties of hepatocytes (Nakamura et al. 1986) and its 
ability to induces scattering of epithelial cells (Stoker et al. 1987). HGF, a disulphide-
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linked α-and β -chain heterodimer with homology to the proteinases of the 
plasminogen family, mediates multiple biological responses by activation of its 
cognate tyrosine kinase receptor c-met (Benvenuti and Comoglio 2007; Corso et al. 
2005). C-met is a tyrosine kinase receptor consisting of an exclusively extracellular α-
chain and a disulphide-linked trans-membrane β-chain that contains a multifunctional 
docking site able to interact with several cytoplasmic signal transducers such as the 
scaffolding adaptor Gab1. Gab1 is crucial in many aspects of c-met signaling, binding 
various signal-relay molecules such as phosphatase Shp2, PI3K, phospholipase C and 
Crk which act upstream of Ras and Raf, two components of the ERK/MAPK pathway 
(Benvenuti and Comoglio 2007; Bolanos-Garcia 2005; Corso et al. 2005).  
C-met activation by HGF is able to evoke a wide array of cellular responses including 
proliferation, migration, scattering, survival, and branched morphogenesis depending 
on cell type and context (Benvenuti and Comoglio 2007; Corso et al. 2005). Notably, 
HGF c-met signaling may play a role in the modulation of disease (Skibinski 2003). 
In many inflammatory diseases, including bacterial meningitis (Nayeri et al. 2000), 
and multiple sclerosis (Kern et al. 2001; Tsuboi et al. 2002), serum and/or local tissue 
concentrations of HGF are increased. In general, HGF is thought to play a beneficial 
role in disease, stimulating repair mechanisms of damaged tissues. However, various 
types of leukocytes including macrophages (Chen et al. 1996; Galimi et al. 2001), 
monocytes (Beilmann et al. 1997; Jiang et al. 2001), dendritic cells (Ovali et al. 2000; 
Rutella et al. 2006), B cells (van der Voort et al. 2000), and T cells (Adams et al. 
1994) have been described to either express c-met and/or show cellular responses to 
HGF indicating possible direct effects of HGF on leukocytes in inflammation. 
Especially for monocytes the evidence is compelling with several studies describing 
the induction of c-met and HGF in human monocytes in response to various 
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inflammatory cytokines. However, the function of HGF/c-met signaling in 
monocytes/macrophages is at present a matter of debate with, functions ranging from 
migration to differentiation reported (Beilmann et al. 1997; Beilmann et al. 2000; 
Chen et al. 1996; Galimi et al. 2001; Jiang et al. 2001). Although HGF/c-met 
signaling may directly influence leukocyte responses in inflammation and 
autoimmune diseases, the mechanisms involved remain at present poorly defined.  
We have investigated the HGF/c-met pathway in experimental autoimmune 
encephalomyelitis (EAE), a well-established mouse model of multiple sclerosis. In a 
previous report we showed that microglia produce HGF in response to TGFβ (Lalive 
et al. 2005). Now we show that both HGF and the HGF receptor c-met are expressed 
in the CNS of EAE diseased mice. Flow cytometric and immunohistochemical studies 
indicate that c-met is primarily expressed by CD11b+ macrophages and to some 
extent by oligodendrocyte progenitor cells (OPCs) but not by T cells or dendritic cells 
(DCs). Complementary in vitro experiments indicated that “classical” but not 
“alternative” activation of macrophages induces c-met expression. Furthermore, we 
show that LPS and TNFα induce c-met through distinct pathways. Functionally 
HGF/c-met signaling does not appear to be involved in cytokine expression, 
phagocytosis or antigen presentation but rather promotes proliferation of activated 
macrophages.  
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MATERIALS AND METHODS 
Mice 
Seven to eight week old C57Bl/6 female mice were purchased from Harlan (the 
Netherlands). TNFαko mice (B6.129-TNF tm1Ljo; (Marino et al. 1997) were obtained 
from the Ludwig Institute for Cancer Research. TNFR1ko mice (Tnfrsf1atm1Blt; 
(Rothe et al. 1993) and TNFR2ko mice (Tnfrsf1btm1Imx; unpublished) were a kind 
gift from Mathias Heikenwälder, University Hospital Zurich, Switzerland. 
Reagents  
Cytokines, growth factors and chemicals were obtained from the following sources. 
Roche Diagnostics: mTNFα and mIFNγ. Sigma: LPS-B5 and -B8. PeproTech: rmIL-
1β, hIL-2, mIL-3, rmIL-4, mIL-6, mL-12, rmIL-13, rmTNFβ, rhTGFβ2, mMip-1α, 
mRANTES, M-CSF, and rhHGF. Pharmingen: hIL-8 and rmIL-10. R&D systems: 
rhTGFβ1 and 3, and IL-17. Calbiochem: L-NMA. Sigma: PMA. Mouse HGF Duoset 
ELISA kit was purchased from R&D systems and used according to the 
manufacturer's instructions.  
Antibodies to c-met were obtained from R&D systems and anti-c-met PY1230/1234/1235 
from Biosource.  Anti-NG2 and PDGF-R (CD140a) were purchased from Chemicon. 
Antibodies to CD4 (RM4-5, Biotin; RM4-4, FITC), CD8 (Biotin, FITC), CD11c 
(HL3, Biotin), CD11b (M1/70, APC, Biotin), CD16/32 (Fc block), CD45 (APC), 
CD80 (16-10A1, FITC), CD86 (GL1, FITC), MHC class II (M5, PE), were obtained 
from BD Pharmingen and F4/80 (FITC) from Serotec. The secondary antibody swine 
anti-goat-PE was purchased from CALTAG and anti-goat HRP and anti-rabbit HRP 
from Pierce. Anti-rat Alexa 488 was obtained from Molecular Probes and 
Streptavidin-FITC from BD Pharmingen 
EAE induction  
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C57BL/6 mice were injected with 100 µg MOG35-55 (Anawa, Switzerland) in 200 µl 
PBS/CFA (DIFCO, USA) (1:1) subcutaneously on the right flank and with 300 ng 
Pertussis toxin (List Biological Laboratories, USA) intraperitoneally (i.p.) on day 0, 
followed by a boost of 300 ng Pertussis Toxin at day 2 and 100 µg MOG35 in CFA 
into the left flank on day 7. The scoring of clinical symptoms was performed as 
described previously (Eugster et al. 1999).  
Isolation of CNS-mononuclear cells  
CNS-mononuclear cells were isolated as described previously (Suter et al. 2003). 
Briefly, brains and spinal cords of animals perfused with Hanks' balanced salt solution 
(HBSS) were minced with a scalpel blade and digested for 30’ at 37°C in HBSS 
containing 50 µg/ml DNase I and 100 µg/ml Collagenase/Dispase (Roche). The 
digestion was quenched on ice and passed through a 100 µm Nylon mesh (BD 
Biosciences) and centrifuged after which the pellet re-suspended in 30% Percoll 
(Sigma). The gradient was centrifuged at 29000 x g for 30 min at 4°C (Kontron 
Instruments, Germany). The top layer containing myelin was removed by aspiration, 
and the interphase containing mononuclear cells was collected, diluted threefold with 
HBSS and collected by centrifugation at 300 x g.  
Primary cells and cell lines 
For the isolation of splenocytes, spleens were removed and mashed through a 100 µm 
cell strainer followed by lysis of erythrocytes in ACK buffer (155 mM NH4Cl, 10 mM 
KHCO3, 0.1 mM EDTA, pH 7.2).  
Peritoneal exudate cells (PECs) were recovered 2 days (optimal for a high recovery of 
macrophages) after i.p. injection of 1 ml 3% Brewer thioglycollate medium (Sigma). 
The peritoneal cavity was flushed with 10 ml HBSS/1% bovine serum albumin 
(BSA)/15 mM Ethylenediaminetetraacetic acid (EDTA).  
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Primary microglial cells were obtained from a co-culture of glial cells as described 
previously (Lalive et al. 2005). Briefly, pups were decapitated and whole brains were 
homogenized mechanically. Brain homogenates were seeded in DMEM (Gibco) 
containing 10% fetal calf serum (FCS) (PAA Laboratories GmbH, Austria), 2 mM N-
Acetyl-L-alanyl-L-glutamine (L-GLU) (Biochrom AG, Germany) and 20 µg/ml 
gentamycin (Sigma) and cultured at 37°C, 8% CO2. On day 14 microglia were 
isolated from the glial feeder layer by mechanical shaking at 1,400 rpm for 25 min.  
Primary oligodendrocyte progenitor cells (OPCs) were isolated as described 
previously (Lalive et al. 2005). Briefly, neonatal forebrain cells were harvested from 
1-2 day old neonates C57/BL6 mice by dissociation of cortices in Papain (Sigma) and 
grown in DMEM supplemented with 10% horse serum (HS) (Gibco) on poly-D-lysine 
(Sigma)-coated cell culture flasks. After 10 days the loosely attached OPCs were 
separated from the glial feeder layer by 16 h of mechanical shaking at 210 rpm, 37°C.  
Bone marrow-derived dendritic cells (BM-DC) prepared as described previously 
(Landmann et al. 2001). 
Bone marrow-derived macrophages (BMM) were prepared from bone marrow cells 
isolated from the femur and tibia. Bones were flushed with HBSS and the cell 
suspension was forced through a 70 µm mesh. Collected cells were re-suspended in 
complete macrophage medium containing DMEM, 30% L929 cell-conditioned 
medium (source of M-CSF), 20% HS, 10 mM HEPES (Gibco) and 10 mM L-GLU 
and cultured at 37°C, 5% CO2. After 7 days virtually 100% of the cells expressed the 
macrophage markers CD11b and F4/80. The cells were harvested by scraping on ice 
and frozen in 90% FCS and 10% DMSO at a density of 5×106-10×106 cells/ml. 
Thawed cells were cultured in either DMEM containing 10% FCS, 2 mM L-GLU and 
20 µg/ml gentamicin or the same medium without serum.  
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OLI-neu cells (kindly provided by Dr. J. Trotter) were cultured in SATO-medium as 
described previously (Lalive et al. 2005).  
To determine c-met expression, all cell types were seeded in 6-well culture plates at 
1.0-1.5×106 cells/well and treated with cytokines for 48 h prior to flow cytometric 
and/or real time PCR analysis. 
Flow cytometric analysis 
Cells were re-suspended in FACS buffer containing 2% FCS, 5 mM EDTA, 0.01% 
NaN3 in phosphate buffered saline (PBS). Prior to staining with the appropriate 
antibodies, Fc receptors were blocked by incubation with anti mouse CD16/32 (Fc-
block, BD Pharmingen). 7-Amino-actinomycin D (7-AAD) was used to exclude non-
viable cells. All flow cytometric data was obtained with a CyFlow flowcytometer 
(Partec, Germany). Data analysis was performed with the freeware program WinMDI. 
c-met immunoprecipitation and Western blotting 
Immunoprecipitation of c-met was based upon a previously published method 
(Moransard et al. 2003) and extensively tested on mouse liver samples and the HEPA 
1-6 cell line (data not shown). Cultured cells were scraped on ice in lysis buffer 
containing 1% Nonidet P 40 (NP-40, Igepal CA 630, Fluka), 50 mM Tris, 150 mM 
NaCl, 5 mM EDTA and a cocktail of proteinase inhibitors (Complete Mini, Roche). 
Spinal cords isolated from EAE diseased mice were homogenized on ice with a 
douncer in the same buffer (NP-40 was added after homogenization). Homogenates 
and lysates were cleared from insoluble material by centrifugation and the 
supernatants were incubated with anti-c-met antibody or isotype control antibody 
followed by incubation with Protein G Dynabeads (Invitrogen). The beads were 
washed with lysis buffer containing 0.5% NP-40 followed by incubation with an 
equal volume of Laemmli buffer at 80°C prior to Western blotting for c-met and 
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phosphorylated c-met. Scanned images of Western blots were quantified using ImageJ 
(Freeware, National Institute of Health, USA) 
Immunohistochemistry 
Mice were CO2 anesthetized and perfused with 25 ml Ringer solution (Braun Medical 
AG, Switzerland). Immunohistochemistry was performed on 10-15 µm frozen, 4% 
PFA- or methanol-fixed longitudinal sections of spinal cord. Sections were thawed, 
fixed and blocked (5% FCS, 0.01% triton, PBS) prior to incubation with primary 
antibody 1/200 in block buffer for 24 h. After washes with PBS, sections were 
incubated with the appropriate secondary antibody and/or Streptavidin-FITC (BD 
Pharmingen) in block buffer for 2 h. After counterstaining with 4’6-diamidino-2-
phenylindole (DAPI, Roche) sections were mounted in Mowiol embedding medium 
(Mowiol 4-88, Calbiochem) containing 0.1% 1,4-Diazabicyclo-82.2.29-octan 
(DABCO, Fluka). 
RNA isolation and real time PCR 
Whole-cell RNA from cultured cells was extracted using the NucleoSpin-RNA II kit 
(Macherey-Nagel, Switzerland). RNA from mouse tissues was extracted by 
homogenisation in TRIzol (Invitrogen) according to the manufacturer’s instructions. 
RNA was reverse-transcribed using random hexamers and AMV reverse transcriptase 
(Promega). The cDNA equivalent to 50 ng of total RNA was PCR-amplified in an 
ABI PRISM 7700 detection system (PE-Applied Biosystems) using TaqMan 
Universal PCR Master Mix (Applied Biosystems) and quantified using the 2-ΔΔCT 
method using 18s rRNA as a housekeeping gene. Relative RNA levels are expressed 
as x-fold variations compared to control. Primers and probes for Taqman analysis for 
IL-1β, IL-6, IL-10, TNFα, and iNOS were purchased from Applied Biosystems. 
Primers and probes for c-met (forward primer 5’-GCA TGT CAG CAT CGC TCA A-
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3’, probe 5’-FAM-TTC AGA GAT CAT CTG CTG CAC TAC TC-3’-TAMRA , 
reverse primer 5’-GGC CCA GCT GTT TCA GTG AA-3’ ) and HGF (forward 
primer 5’-TGG TGG CCC ACT CAT TTG T-3’ , probe 5’-FAM-AAA TGA GAA 
TGG TTC TTG GTC TCA TT-3’-TAMRA, reverse primer 5’-ATT TGG GAT GGC 
ACA TCC A-3’ ) were purchased from Microsynth, Switzerland. 
Nitrate test (Griess test) 
Medium aliquots (in triplicate) from LPS or LPS + IFNγ treated BMM cultures co-
treated with or without 50 ng/ml HGF were incubated in a 96 well plate with 0.04% 
Napthylethylenediamine-dichloride (Sigma), 0.4% Sulfanylamide (Sigma) and 1.2% 
H3PO4 at RT for 10 minutes. After determination of the absorption at 540 nm on a 
plate reader, the concentration of nitrite in the medium was calculated using a 
standard curve of serial dilutions from a 512 µM NaNO2 stock solution. 
MTT cell viability assay 
BMM were seeded in a 96 well plate and treated with LPS for 16 h prior to the 
addition of 50 ng/ml HGF or carrier only, followed 1h later by the addition of 
camptothecin (Sigma) or staurosporine (Sigma) at various concentrations. 20 µl of a 5 
mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma) 
solution was added followed by incubation at 37°C for 5 h. After removal of the 
medium and the addition of DMSO, the absorbance was measured on a plate reader at 
550 nm. 
Phagocytosis assay 
BMM were grown on 6 well plates and treated with LPS or left untreated. 50 ng/ml 
HGF was added 1 h prior to addition of 1 µm PE-labelled carboxylated polystyrene 
beads (Polysciences USA) for 30 minutes. The cells were extensively washed with 
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FACS buffer, harvested by scraping on ice and re-suspended in FACS buffer for flow 
cytometric analysis.  
Proliferation assay 
BMM at various concentrations were seeded in a 96 well plate and treated with LPS 
for 16 h before the addition of 5 µCi/ml 3H-thymidine (GE Healthcare) together with 
or without 50 ng/ml HGF. After incubate for 16 h at 37°C the cells were harvested 
directly onto a glass fiber filter membrane using a 96-well plate harvester. The filters 
were dried at 60°C, sealed in a plastic bag containing scintillation fluid (PerkinElmer) 
and measured in a beta-counter (PerkinElmer). 
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RESULTS 
HGF, c-met expression and c-met phosphorylation are increased in the CNS of 
mice with EAE. 
HGF mRNA expression was examined by quantitative RT-PCR in the spinal cord of 
MOG35-55 immunized mice at different EAE disease stages. On day 10 post-
immunization (p.i.), before clinical signs were present (preclin), HGF mRNA levels 
were comparable to those in naïve mice, whereas at the peak of disease (d16-18 p.i., 
average score 3.33±0.17), HGF mRNA levels were significantly elevated 
(688%±115). In the remission phase (d31 p.i., average score 1.75±0.11), HGF mRNA 
levels were still elevated although significantly reduced compared to the levels at 
peak disease (380%±140) (Fig. 1A). 
Measurement of HGF protein levels in the spinal cord (Fig. 1B) and serum (Fig. 1C) 
with ELISA showed that at the onset of disease (d14 p.i., average score 0.25±0.14). 
HGF levels in spinal cord (1.76±0.29 ng/mg protein) and serum (2.72±0.26 ng/ml) 
were comparable to those found in naïve mice (2.27±0.28 ng/mg protein, 2.98±0.37 
ng/ml respectively). In contrast, HGF amounts in mice at the peak of disease (day 16-
18 p.i., average score 3.10±0.19) were significantly elevated in both spinal cord 
(6.57±0.97 ng/mg protein) and serum (4.57±0.33 ng/ml), with the largest increase 
found in the spinal cord (2.9 fold). At the remission phase (day 44 p.i., average score 
2.20±0.12), serum HGF levels (3.07±0.45 ng/ml) returned to values found in naïve 
mice, whereas HGF amounts in spinal cord (3.92±0.14 ng/mg protein) remained 
slightly elevated. Thus, the expression of HGF mRNA in the CNS and the higher 
amounts of HGF protein in the CNS compared to serum indicate a source of HGF 
within the CNS rather than in the periphery, as we have suggested in an earlier report 
(Lalive et al. 2005).  
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The observed increase in HGF levels led us to examine the expression of the HGF 
receptor c-met in the spinal cord at the different disease stages. Quantitative RT-PCR 
showed that c-met mRNA was elevated at both peak (day 18 p.i.) and remission (day 
31 p.i.) but not at the preclinical stage (day 10 p.i.) (Fig. 1D). Analysis of c-met 
protein in the spinal cord at the different disease stages by immuno-precipitation and 
Western blotting showed that c-met protein amounts were elevated at all disease 
stages (Fig. 1E lower panel) with significant increases at peak and remission (Fig. 
1F). Importantly, western blotting with anti pY1230/1234/1235 c-met antibody (detects 
activated c-met) showed that c-met phosphorylation is significantly increased at all 
disease stages with phosphorylation reaching a maximum at peak disease (Fig. 1E, 
upper panel and Fig. 1G). Taken together, these data show that the increase in HGF 
and c-met, as well as the activation of c-met, correlate with the peak phase of EAE, 
suggesting a pro-inflammatory role for HGF signalling in EAE. 
 
The HGF receptor c-met is predominantly expressed by macrophages in EAE. 
Various types of leukocytes, glia and neurons are able to express c-met (Birchmeier 
and Gherardi 1998; Kilpatrick et al. 2000; Shimazaki et al. 2003; Tyndall and 
Walikonis 2006; Yan and Rivkees 2002). Therefore we determined which cells 
express c-met in the spinal cord during the course of EAE by immunohistochemistry. 
Strikingly, at peak disease c-met expression was confined to large clusters of 
infiltrating leukocytes, easily identified by DAPI nuclear stain (Fig. 2A-E). Co-
staining for c-met and markers for oligodendrocyte precursor cells (OPCs), 
macrophages, dendritic cells (DCs) and T cells showed that at peak EAE c-met is 
mainly found on CD11b+ macrophages although not all CD11b+ cells expressed c-met 
(Fig. 2C). C-met expression was also found on a small number of CD11c+ dendritic 
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cells (Fig. 2D) but never on CD4+ T cells (Fig. 2E). In addition, a modest number of 
NG2+ cells expressed c-met (Fig. 2A), whereas PDGFR+ cells, although found in 
close proximity to c-met+ clusters of cells, did not appear to express c-met themselves 
(Fig. 2B). Both NG2 and PDGFR are commonly used markers for oligodendrocyte 
progenitor cells (OPCs). At the remission phase, c-met+ cells were no longer observed 
although small numbers of CD11b+ cells were still detectable (Fig 2F). 
In addition, flow cytometric analysis was used to determine c-met expression on 
leukocytes in the periphery during EAE. Clearly, a small population of c-met+ cells 
was present in the spleen at peak disease that was not present at the onset or remission 
phase of disease or in naïve mice (Fig. 3A). Further analysis of splenocytes isolated 
from peak EAE diseased animals showed that approximately 43% of the CD11b+ 
cells are c-met+ whereas CD4+ and CD8+ T cells did not express c-met (Fig. 3B and 
C). Collectively, these data indicate that c-met is mainly expressed by CD11b+ 
macrophages in the CNS and spleen at peak EAE disease. 
 
Activated macrophages and OPCs, but not microglia or DCs, express c-met. 
Our observations indicated that the majority of c-met+ cells in the spinal cord are 
CD11b+ macrophages. To assess if c-met is in general expressed by macrophages we 
determined c-met expression in bone marrow-derived (BMM) and peritoneal 
macrophages by flow cytometry. Interestingly, although quiescent BMM in vitro did 
not express c-met, treatment with LPS or TNFα led to robust expression (Fig. 4F) 
indicating that only activated macrophages express c-met. In good agreement, 
peritoneal exudate cells (PECS), isolated 48h after induction of sterile peritonitis by 
thioglycollate injection, contained a population of c-met+ cells expressing the 
macrophage markers CD11b and F4/80 (Fig. 4E).  
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The CD11b+/c-met+ cells we observed in the spinal cord at peak EAE may originate 
from CNS-resident microglia or blood-derived macrophages. In vitro however, both 
BV2 cells, a well-established microglial cell line (Bocchini et al. 1992), and primary 
microglia did not express c-met even after activation with LPS or TNFα (Fig. 4A and 
3B). 
In addition to CD11b+ macrophages, a small number of DCs and OPCs expressed c-
met at peak EAE in the spinal cord. However, in vitro, both untreated and LPS-
activated murine bone marrow derived DCs (BMDCs) failed to express c-met (Fig. 
4C). In contrast, OLI-neu cells, a well-established OPC cell line (Jung et al. 1995) 
displayed a modest c-met expression upon TNFα + IFNγ treatment (Fig. 4D). 
Treatment with only TNFα had no effect on c-met expression.  
Thus, in vitro, c-met expression can be induced in macrophages and to a limited 
degree in OPCs, but not in microglia and DCs. Moreover, in vivo, inflammatory 
conditions induce c-met expression in peritoneal macrophages. 
 
LPS and TNFα induce c-met expression in macrophages through independent 
pathways in a dose and time-dependent manner. 
The robust expression of c-met by BMM led us to focus our efforts on the regulation 
of c-met expression in macrophages. First, we confirmed our flow cytometric 
observations by c-met immunoprecipitation from cultured BMM treated with TNFα 
or LPS. Both stimuli induced c-met protein expression in otherwise c-met negative 
BMM (Fig. 5A). Importantly, treatment of LPS-activated BMM with recombinant 
HGF triggered phosphorylation of c-met indicating receptor activation (Fig. 5B). 
Furthermore, a time course study showed that phosphorylation of c-met is rapid, 
occurring within 5 minutes of HGF addition (data not shown).  
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Dose-response studies showed that 25 ng/ml TNFα or 10 ng/ml LPS are sufficient to 
trigger maximum c-met expression (Fig. 5C). A time course study showed that LPS 
and TNFα-induced c-met expression is remarkably slow; maximum receptor 
expression was only reached after 40h (Fig. 5D). Notably, c-met mRNA expression in 
response to LPS also required several hours and expression increased progressively 
over time (Fig. 5E). Thus both TNFα and LPS induce expression of functional c-met 
in a time and dose dependent manner.  
Since LPS-activated macrophages produce large quantities of TNFα (Fujihara et al. 
2003), LPS-induced c-met expression could potentially result from autocrine TNFα 
signaling. Quantitative RT-PCR showed that indeed TNFα mRNA expression 
preceded c-met mRNA expression by several hours (Fig. 5E). To further investigate 
this possibility, we treated BMM from TNFα receptor 1 (TNFR1ko), TNFα receptor 2 
(TNFR2ko) and TNFα (TNFαko) deficient animals with either LPS or TNFα. 
Immunoprecipitation of c-met showed that TNFα did not induce c-met expression in 
TNFR1ko BMM but did trigger c-met expression in TNFR2ko and TNFαko BMM. 
Thus TNFα induces c-met expression in BMM through TNFR1 signaling. Importantly 
however, LPS was able to induce c-met protein expression in TNFR1ko, TNFR2ko 
and TNFαko BMM, clearly showing that LPS-induced c-met expression in 
macrophages does not require TNFα signaling (Fig. 5F). 
 
Alternative activation of macrophages does not induce c-met expression and does 
not prevent or alter c-met expression induced by TNFα or LPS. 
To investigate which other stimuli besides TNFα and LPS are able to induce c-met 
expression, we treated BMM cultures with different cytokines, chemokines and 
chemicals (Supplementary Table 1). Remarkably of all the stimuli tested, only TNFα 
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and LPS induced c-met expression whereas other pro-inflammatory cytokines 
important in the progression of EAE such as IL-6, IL-12 and IL-17 do not (Fig. 6A). 
Notably, co-treating BMM with IFNγ did not enhance LPS- (Fig. 6A) or TNFα-
induced (data not shown) c-met expression. Importantly, alternative activation of 
macrophages with IL-4, IL-13 or IL-10 did not induce c-met expression either (Fig. 
6A). Potentially, de-activation (or a change in activation status) of classically 
activated BMM could alter c-met expression or, vice versa, alternative activation of 
BMM could prevent LPS-induced c-met expression. However, further flow 
cytometric analysis showed that IL-10 or IL-13 treatment does not alter c-met 
expression induced in response to LPS (Fig. 6B) and that BMM activated with IL-4, 
IL-10, or IL-13 still respond to LPS with an increase in c-met expression (Fig. 6C). In 
contrast, treatment of LPS-activated BMM with recombinant HGF did show that c-
met in macrophages can be down regulated by its natural ligand (Fig. 6B). 
Quantitative analysis of the mean fluorescence intensity (MFI) of c-met expression 
showed that LPS and TNFα treatment induce a comparable expression (207%±19 and 
200%±48, respectively), that IL-10 does not down-regulate LPS-induced c-met 
(192%±31) and that HGF-treatment leads to a small but significant reduction in LPS-
induced c-met expression (173%±12, p=0.01). Collectively, these data indicate that 
only the classic activators of macrophages induce c-met expression. 
 
HGF induces proliferation of LPS-activated macrophages but does not modulate 
classic macrophage functions. 
We next assessed whether HGF can modulate classical macrophage functions. 
Cytokine secretion and NO production by macrophages are important in the 
progression of EAE and are the main cause of myelin and axonal damage (Hendriks 
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et al. 2005). Quantitative RT-PCR analysis of the transcript levels of iNOS, c-met, 
and the cytokines IL-1β, IL-10, and TNFα in LPS-activated BMM after 1, 7 or 16h 
HGF treatment (Fig. 7A) showed that HGF does not significantly alter the expression 
of these transcripts. IL-6 showed a trend towards up-regulation although not 
significant. In addition, transcript levels of the cytokine receptors IL-1R, IL-2R, IL-
10R and the anti-apoptotic proteins Bcl-2 and Bcl-xL were unaffected by HGF 
treatment (data not shown). Furthermore, HGF did not alter the amount of nitrite 
produced by LPS-activated BMM (Fig. 7B). Notably, the addition of IFNγ together 
with LPS significantly increased the amount of nitrite produced but also in this setup 
HGF did not alter nitrite production (Fig. 7B). 
In addition to their role in innate immunity, macrophages can contribute to adaptive 
immune responses through the presentation of antigenic peptides on MHC molecules 
(Becher et al. 2006; Hume 2008). Flow cytometric analysis revealed that only a 
minority of LPS-activated BMM expresses MHC class II molecules and that the co-
stimulatory molecules CD80 and CD86 are expressed at very low levels (Fig. 7C, 
upper panels). Notably, treatment with HGF did not alter the expression levels of 
these molecules or the levels of CD45, CD11b or F4/80 (Fig. 7C, lower panels).  
Macrophages are essential in the recovery from EAE removing myelin debris by 
phagocytosis, a process critical for remyelination (Franklin and Ffrench-Constant 
2008). We assessed the effect of HGF on the phagocytic capacity of macrophages by 
incubating BMM with PE-labeled polystyrene beads followed by flow cytometric 
analysis. Although LPS treatment dramatically enhanced the phagocytic capacity of 
BMM, 4, 16 or 40h of HGF treatment did not influence phagocytosis (Fig. 7D).  
HGF can elicit diverse responses in a wide variety of cells including proliferation, 
migration and protection form apoptosis (Benvenuti and Comoglio 2007; Corso et al. 
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2005; Ma et al. 2003; Stuart et al. 2000). To determine if HGF is able to protect BMM 
from apoptosis, LPS-activated cells were challenged with increasing concentrations of 
camptothecin. One hour pre-treatment with HGF before the addition of camptothecin 
had no significant influence on LPS-activated BMM viability (Fig. 7E, first columns). 
Comparable results were obtained with staurosporine (data not shown). Importantly 
however, we noted an approximately 30% increase in metabolic activity in control 
BMM treated with HGF but not challenged with camptothecin suggesting that HGF 
may induce proliferation (Fig. 7E). Indeed 3H-thymidine incorporation assays showed 
significantly increased proliferation of LPS-activated BMM upon HGF treatment 
(269%±10, p=0.001) (Fig. 7F) whereas the proliferation of quiescent BMM was 
unaffected by HGF (not shown). In summary, these data indicate that, in vitro, HGF 
has no effect on classic macrophage functions such as cytokine and NO secretion, 
phagocytic activity, and antigen presentation. Rather, HGF enhances the proliferation 
of LPS-activated macrophages without preventing apoptotic death. 
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DISCUSSION 
 
HGF and c-met expression in EAE 
In this report we show that in EAE at peak disease both HGF and its receptor c-met 
are expressed in the spinal cord and that c-met is activated. The elevated HGF levels 
in the CNS in acute EAE correspond well with the elevated levels of HGF found in 
the CSF of patients with multiple sclerosis in the relapsing acute phase (Tsuboi et al. 
2002). In general, the activation of c-met correlated well with HGF expression, except 
that in some animals at the onset of disease, c-met was activated although HGF levels 
were still comparable to those in naïve animals. This apparent contradiction may be 
explained by, for example, the cellular location of the receptor; initial intracellular c-
met may be transported to the plasma membrane at the onset of EAE where it would 
then be available for activation by HGF. Alternatively, natural occurring c-met 
antagonist such as NK1 and 2 and NK4-like protein (Chan et al. 1991; Raymond et al. 
2006), both splice variants of full length HGF, may inhibit c-met activation in the 
CNS under systemic conditions. CNS injury may down regulate the levels of these 
antagonists, allowing c-met activation without a preceding increase in HGF.  
We show c-met expression is limited to the peak phase of disease, confined to clusters 
of infiltrating cells in the CNS and mainly expressed by macrophages. Although both 
DCs and macrophages have been described to be able to express c-met (Chen et al. 
1996; Galimi et al. 2001; Ovali et al. 2000; Rutella et al. 2006), in the CNS the 
majority of the c-met co-localizes with CD11b and not with CD11c, suggesting that 
only a small population of DCs express c-met. In addition, our in vitro observations 
indicate that both naïve and LPS-matured BMDCs do not express c-met whereas 
LPS- and TNFα-activated BMM show a robust c-met expression. Although a 
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microglial origin of the c-met+/CD11b+ cells in the CNS of EAE diseased animals 
cannot be excluded at present. However, both cultured primary microglia and the 
microglial cell line BV2 failed to express c-met in response to stimuli that elicit 
significant c-met expression in BMM, suggesting a CNS-infiltrating macrophage 
rather than a microglial origin of the c-met+/CD11b+ cells. Importantly the expression 
of c-met on CD11b+ splenocytes may indicate that cmet+/CD11b+ cells migrate 
between the spleen and CNS, a notion supported by the chemotactic properties of 
HGF for many cell types (Benvenuti and Comoglio 2007; Corso et al. 2005). 
However, the presence of macrophages in the CNS at the onset phase of EAE, prior to 
the expression of c-met on splenic macrophages contradicts such a scenario. 
Notably, c-met staining co-localized only with one of two OPC markers tested. This 
apparent discrepancy may be explained by the observation that macrophages in CNS 
lesions can express NG2 ((Bu et al. 2001; Jones et al. 2002), and unpublished 
observations). However, expression of c-met by OPCs during EAE seems likely since 
our in vitro data and data from others (Yan and Rivkees 2002) show that c-met can be 
induced by TNFα  + IFNγ in OLI-neu cells, both cytokines present at high 
concentrations in the CNS at peak disease. Interestingly, TGFβ, a cytokine that can 
induce differentiation and apoptosis of OPCs in vitro, had no effect on c-met 
expression (McKinnon et al. 1993; Schuster et al. 2002). The expression of c-met by 
OPCs and the role of HGF/c-met signaling in these cells during EAE will require 
further study which lies outside the scope of the present report.  
Surprisingly of all the different stimuli tested only TNFα and LPS were able to induce 
c-met expression in macrophages. C-met expression by macrophages is poorly 
described, however a number of groups have studied c-met expression in human 
peripheral blood monocytes (PBMCs), which can give rise to tissue macrophages. 
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These reports establish that monocytes are able to express c-met but the precise 
conditions required differ significantly. Our data is in good agreement with some 
studies that show induction of c-met expression in human monocytes by pro-
inflammatory mediators such as TNFα + IL-6, TNFα + IFNγ and LPS (Beilmann et 
al. 2000; Chen et al. 1996; Galimi et al. 2001) but contrasts with the findings of others 
that report IL-1-, IFNγ- and IL-10-induced up-regulation of c-met mRNA (Galimi et 
al. 2001; Jiang et al. 2001). Inconsistencies between these studies and the present 
study are probably due to species (human versus murine) and cell type (peripheral 
blood monocyte versus bone marrow-derived macrophage) differences. However, in 
general, pro-inflammatory stimuli appear to induce c-met expression in monocytes 
and macrophages. 
Recent research efforts have led to the division of polarized macrophages into 
different classes based upon the polarizing stimulus and the resulting functional 
capacity (Martinez et al. 2008; Mosser and Edwards 2008). Classically activated or 
M1 macrophages develop in response to stimulation with IFNγ and TNFα or 
microbial products such as LPS and are characterized by their enhanced ability to 
secrete pro-inflammatory cytokines, endocytosis, and ability to kill intracellular 
pathogens. Alternatively activated macrophages (M2 macrophages) are critical in type 
II inflammation, resolution of inflammation, and tissue repair. M2 macrophages 
express high levels of arginase 1 and, depending on subtype, are induced by IL-4 or 
IL-13, Fcγ receptor + Toll receptor activation, or deactivation by stimuli such as 
glucocorticoids, IL-10 or TGFβ (M2a, M2b, M2c, respectively).  
Our data show that c-met is preferentially expressed by classically activated M1 
macrophages since only TNFα and LPS were able to elicit c-met expression whereas 
IL-4, IL-13 and IL-10 failed to induce c-met despite increased arginase activity, a 
	   24	  
hallmark of M2 macrophages (data not shown). Notably, IL-4, IL-13 and IL-10 also 
failed to down regulate LPS-induced c-met and alternatively activated macrophages 
still up-regulated c-met expression in response to LPS. By inference, these 
observations imply that CD11b+/c-met+ macrophages in the CNS at peak EAE disease 
classify as M1 cells. Intriguingly, although classical activation of macrophages 
normally requires IFNγ in combination with LPS or TNFα and IFNγ significantly 
enhanced the NO production by LPS-activated BMM, it is not required for LPS- or 
TNFα-induced c-met expression in BMM. In addition, we provide evidence that 
TNFα and LPS induce c-met expression in macrophages through two independent 
pathways and that TNFα triggers c-met expression through TNFR1 signaling and not 
through TNFR2 signaling. LPS- or TNFα-induced c-met expression appears to be 
remarkably stable and occurs irrespective of the prior polarization “flavor” of the 
macrophage.  
 
Function of HGF signaling in macrophages  
We show that cytokine expression is unaltered by HGF treatment of LPS-activated 
BMM, although others have reported HGF-induced increases in chemokines, 
interleukins, growth factors, and NO in human monocytes (Beilmann et al. 2000; 
Galimi et al. 2001), In addition, both iNOS mRNA expression and NO production 
were unaltered by HGF. Thus, intriguingly the production of cytokines and NO 
appears not to be regulated by HGF in macrophages. Furthermore, a role for HGF 
signaling in antigen presentation or phagocytosis by macrophages seems unlikely 
because the expression of MHC class II, and the co-stimulatory molecules CD80 and 
CD86, were unaltered by HGF treatment of LPS-activated macrophages as was their 
capacity to phagocytose polystyrene beads.  
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Well-established cellular responses to HGF include enhanced cell growth, 
invasion/migration and protection from apoptosis. In our experiments, HGF failed to 
protect cultured macrophages from camptothecin or staurosporine-induced cell death 
suggesting that HGF cannot prevent apoptosis in this cell type. 
We attempted to assess macrophage migration using a modified Boyden chamber 
trans-well system. Although Mip-1α improved the migration rate of untreated BMM, 
the migration rate of LPS-pretreated BMM was unaltered by Mip-1α or HGF (data 
not shown). Notably because LPS-treated BMM are strongly adherent, which may 
account for the poor migratory response towards Mip-1α, an alternative migration 
assay that determines the invasiveness of macrophages into collagen or matrigel for 
example may be more appropriate. Thus a role for HGF in macrophage migration 
requires further investigation. 
However, HGF did elicit a clear increase in proliferation of LPS-activated 
macrophages whereas quiescent macrophages were unaffected. These observations 
suggest that HGF promotes the proliferation of activated macrophages within the 
CNS in acute EAE, a concept that has profound implications. It would be tempting to 
speculate that inhibition of HGF signaling may ameliorate the peak phase of EAE by 
reducing the number of activated macrophages in the CNS. 
In this respect it is important to note that in EAE, a potential pro-inflammatory role 
for HGF signaling in macrophages is supported by a number of our observations. 
Firstly, c-met+/CD11b+ macrophages, HGF, and activated c-met are most abundant in 
the CNS at the peak phase of EAE. Secondly, the pro-inflammatory cytokine TNFα, 
which induces c-met expression in cultured macrophages, is highly elevated at this 
disease stage and plays a crucial role in EAE progression (Probert et al. 2000). 
Thirdly, IL-4, IL-13 and IL-10 all play important roles in the resolution of 
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inflammation and initiation of tissue repair, but fail to modulate c-met expression on 
classically activated macrophages. Intriguingly, our data advocates that c-met 
expression by activated macrophages may be not limited to EAE but could be a more 
general feature of macrophages during an inflammatory response. It is interesting to 
note that in many diseases, such as arthritis (Feuerherm et al. 2001) and lupus 
nephritis (Ferraccioli and Romano 2008), the expression of HGF and/or c-met are 
likely to coincide with the presence of macrophages at the inflammatory site.  
In summary, our data indicate that HGF/c-met signaling in macrophages may play a 
pro-inflammatory role in EAE and that c-met could serve as an important therapeutic 
target in MS. In the light of the current interest in HGF/c-met modulating therapies, it 
is becoming a pressing issue to investigate the role of HGF signaling in macrophages 
in a broader scope.  
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FIGURE LEGENDS 
Figure 1. HGF and the HGF receptor c-met are expressed at peak and remission 
of EAE in the spinal cord. (A) Analysis of HGF mRNA expression in spinal cord at 
different EAE stages by quantitative RT-PCR. HGF mRNA expression was 
significantly increased at peak and remission. Bars represent mean ± SEM of 3 
animals per time point. (B and C) HGF protein levels were measured with ELISA in 
spinal cord lysates (B) and serum (C). HGF levels were significantly elevated in 
spinal cord at peak and remission and in serum at peak disease. Bars represent mean ± 
SEM of 4 to 5 animals per time point. (D) Analysis of c-met mRNA expression in 
spinal cord by quantitative RT-PCR. C-met expression is significantly increased at 
peak and remission. Bars represent mean ± SEM of 3 animals per time point. (E) C-
met immunoprecipitation from spinal cord lysates followed by western blotting for 
phosphorylated c-met (top panel) and total c-met (lower panel). Phosphorylation of 
Tyr1230/1234/1235 (activation) of c-met is increased at onset, peak and remission. C-met 
protein levels are elevated at the same EAE stages. Shown is a representative 
experiment of 4. (F and G) Densitometric analysis of the experiments described in E. 
Compared to naïve mice, c-met protein is significantly increased in amount (F) and 
phosphorylation (G) at peak and remission. The highest c-met protein amounts are 
found at remission and c-met phosphorylation is highest at peak. The quantification of 
c-met phosphorylation is normalized to total amount of c-met immunoprecipitated. 
Results are expressed as the mean ± SEM of 4 animals per time point. *P<0.05, 
**P<0.01, ***P<0.001 versus naïve control or as indicated by brackets; Students T-
test. 
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Figure 2. C-met is predominantly expressed by macrophages in the spinal cord 
at peak EAE. (A-E) Immunohistochemistry for c-met and cellular markers in spinal 
cord. At peak EAE, c-met (second column) is confined to areas with high numbers of 
infiltrating cells, easily identified in the DAPI staining (third column) as clustered 
nuclei. First column shows the expression of the cellular marker indicted and the 
fourth column shows the merged images of the preceding columns. Last column 
shows an electronically 5x magnified image of the boxed area in the third column. (A) 
C-met co-localizes with the OPC marker NG2 (arrows). Many c-met positive cells are 
NG2 negative (arrowheads). (B) C-met does not co-localize with PDGFR (star), an 
alternative OPC marker. (C) Many CD11b+ macrophages are c-met positive (arrows). 
(D) C-met co-localisation with CD11c+ dendritic cells is less frequently observed. (E) 
CD4+ T cells do not co-localise with c-met. (F) In the remission phase, c-met 
expression is no longer observed (second column). (A-F) Arrows indicate co-
localization of the indicated cellular marker with c-met. Arrowheads depict c-met 
positive cells that do not co-localize with that marker. Scale bars in the first 4 
columns represent 200 µm and 50 µm in the last column. 
 
Figure 3. C-met is expressed by CD11b+ splenocytes at the peak phase of EAE. 
Flow cytometric analysis of c-met expression by splenocytes isolated at different 
disease stages. (A) C-met expression is detected at peak EAE on a small population of 
splenocytes (gated for total live splenocytes). (B) Splenocytes isolated at peak EAE 
were co-stained with antibodies against c-met, CD11b, CD4 and CD8. Approximately 
43% of CD11b+ splenocytes at peak EAE express c-met (third panel). CD4+ and 
CD8+ splenocytes are c-met negative (first and second dot plot respectively). Fourth 
dot plot shows isotype control for anti-c-met antibody. (C) Gating on CD11b+ cells 
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shows that c-met expression is limited to the peak phase of EAE. (A-C) Grey area: 
isotype control. Results shown are from a representative experiment of 2 EAE series 
with 3 mice each per time point. 
 
Figure 4. C-met expression can be induced in OPCs and macrophages but not in 
microglia and dendritic cells. Flow cytometric analysis of c-met expression by 
different cell types. (A) C-met is not expressed by untreated BV2 cells and cannot be 
induced by treatment with LPS. (B) C-met expression cannot be detected on 
untreated, LPS- or TNFα-treated primary microglia. (C) Untreated and LPS-treated 
BMDCs cells do not express c-met. (D) Treatment of OLI-neu cells with TNFα + 
IFNγ induces c-met expression. Untreated and TGFβ-treated OLI-neu cells are c-met 
negative. (E) PECs express c-met on a sub-population of cells. Gating for c-met+ cells 
shows that these cells are all CD11b and F4/80 positive. (F) Treatment with TNFα or 
LPS induces c-met expression in BMM whereas untreated BMM do not express c-
met. (A-F) Grey area: isotype control. Thin line: c-met expression of untreated cells. 
Thick line: c-met expression after the indicated stimulus. TNFα 25 ng/ml, IFNγ 100 
U/ml, LPS 100 ng/ml, TGFβ 5 ng/ml (40h). 
 
Figure 5. Activation of macrophages by LPS or TNFα induces c-met, in a time- 
and dose-dependent manner, which can be activated by exogenous HGF. (A) C-
met immunoprecipitation (IP) from cultured BMM followed by western blotting for c-
met. C-met protein is expressed after macrophage activation with LPS or TNFα (16h) 
but is absent in untreated macrophages. No Ab: beads-only IP control. No lysate: IP 
without BMM lysate. (B) C-met immunoprecipitation from LPS-activated BMM 
followed by western blotting for phosphorylated c-met (top panel) and total c-met 
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(lower panel). C-met protein is activated (phosphorylated at Tyr1230/1234/1235) in BMM 
in the presence of HGF (50 ng/ml, 1h). (C) LPS- and TNFα dose dependent c-met 
protein expression in BMM analysed by flow cytometry. Treatment with 10 ng/ml 
LPS or 25 ng/ml TNFα (40h) is sufficient to induce maximum c-met levels. (D) Time 
course of LPS- and TNFα-induced c-met protein expression in BMM analysed by 
flow cytometry. Maximum c-met levels are obtained after 40h of treatment with either 
100 ng/ml LPS or 25 ng/ml TNFα. (C-D) Grey area: isotype control. (E) Quantitative 
RT-PCR analysis for TNFα and c-met of a time-course of LPS treatment of BMM. 
LPS-induced TNFα mRNA expression (grey bars) precedes c-met mRNA expression 
(black bars). (F) C-met immunoprecipitation (IP) from wt, TNFR1ko, TNFR2ko, and 
TNFαko BMM cultures followed by western blotting for c-met. TNFα and LPS 
induce c-met protein expression in wt, TNFαko and TNFR2ko BMM, but only LPS 
induces c-met protein expression in TNFR1ko BMM. BMM were treated with LPS or 
TNFα for 40h. No Ab: beads-only IP control. No lysate: IP without BMM lysate. (A-
F) Data are from representative experiments. Bars represent mean ± SEM.  
 
Figure 6. Alternative activation of macrophages does not induce c-met 
expression and does not prevent or reverse LPS-induced c-met expression. Flow 
cytometric analysis of BMM treated with various cytokines and combinations thereof. 
(A) C-met expression can only be induced by LPS and TNFα but not with any of the 
other stimuli. Grey area: isotype control. Thin line: c-met expression of untreated 
cells. Thick line: c-met expression after 16h treatment with the indicated stimulus. (B) 
LPS-induced c-met on BMM is not altered by subsequent treatment with IL-10 or IL-
13 but is down regulated by its ligand HGF. Thin line: c-met expression of untreated 
cells. Thick line: c-met expression after 16h LPS treatment. Grey line: c-met 
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expression after 16h of treatment with LPS followed by removal, wash and 16h 
treatment with the indicated stimulus. (C) Alternative activation of BMM with IL-4, 
IL-10 or IL-13 does not induce c-met expression and does not prevent LPS-induced 
expression of c-met in BMM. Thin line: c-met expression of untreated cells. Grey 
line: c-met expression after 16h treatment with the indicated stimulus. Thick line: c-
met expression after 16h of treatment with the indicated cytokine followed by 
removal, wash and 16h treatment with LPS. Shown are histograms representative of 
at least 3 experiments for each stimulus. Concentrations used are indicated in Table 1. 
 
Figure 7. HGF enhances macrophage proliferation but does not modulate classic 
macrophage functions. (A) Quantitative RT-PCR for various cytokines, iNOS and c-
met in BMM after treatment with LPS and/or HGF. HGF does not modulate cytokine 
mRNA expression in LPS-treated BMM. White bars: 16h LPS. Grey bars: 16h LPS 
followed by removal, wash and 16h HGF. Black bars: 16h LPS + HGF followed by 
removal, wash and 16h HGF. Data are from 5 independent experiments. Bars 
represent mean ± SEM. (B) Griess test measuring nitrite concentration in medium 
from LPS-treated BMM cultures. HGF treatment does not alter nitrite production by 
BMM. Black bars: 16h LPS followed by removal, wash and 16h HGF or no 
treatment. Grey bars: 40h LPS with or without HGF. Striped bars: 40h LPS + IFNγ 
with or without HGF. Data are from 3 independent experiments. Bars represent mean 
± SEM. (C) Flow cytometric analysis of LPS-treated BMM for different macrophage 
markers, co-stimulatory molecules and MHC-II. 16h HGF treatment of LPS-treated 
BMM (lower panels) does not alter expression levels of the indicated markers 
compared to LPS-only treated BMM (upper panels). One representative experiment of 
3 with similar results is shown. (D) BMM phagocytosis of PE-labelled polystyrene 
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beads. BMM were either left untreated (thin line), treated with LPS for 40h (thick 
line) or treated with LPS for 40h with addition of HGF in the last hour (grey line) 
prior to addition of PE-labelled beads for 30 minutes. One representative experiment 
of 3 with similar results is shown. (E) Survival of camptothecin-treated LPS-activated 
BMM was determined using a MTT assay. LPS-activated BMM are susceptible to 
camptothecin-induced (16h) apoptotic death in a dose-dependent manner (black bars). 
1h pre-treatment with HGF prior to addition of camptothecin in the continued 
presence of HGF does not prevent apoptosis (grey bars). One representative 
experiment with triplicate cultures of 2 experiments with similar results is shown. (F) 
Proliferation of LPS-treated BMM was assessed by 3H-thymidine incorporation (16h). 
Continuous presence of HGF during the labelling period significantly enhanced 
proliferation of LPS-activated BMM. Data are from 3 independent experiments. Bars 
represent mean ± SEM. ***P<0.001 versus control; Students T-test. 
Table 1. Cytokines tested for c-met induction on BMM. 
 
Treatment for 40h, analyzed by flow cytometry 
* Concentration used in Fig. 6 	  
Stimulus Concentration c-met regulation? 
IL-1β 10, 30* ng/ml No 
IL-2 20*, 100 ng/ml No 
IL-3 20 ng/ml No 
IL-4 10* U/ml No 
IL-6 20* ng/ml No 
IL-8 20* ng/ml No 
IL-10 10, 20, 30* ng/ml No 
IL-12 100* ng/ml No 
IL-13 10, 30* ng/ml No 
IL-17 100* ng/ml No 
Mip-1α 75, 150, 225 ng/ml No 
RANTES 50, 100, 150 ng/ml No 
TGFβ1 0.2, 2, 20 ng/ml No 
TGFβ2 0.2, 2, 20 ng/ml No 
TGFβ3 0.2, 2, 20 ng/ml No 
IFNγ 5, 10, 20*, 50, 100 ng/ml No 
TNFα 5, 10*, 20, 50, 100 ng/ml Up 
TNFβ 10 ng/ml No 
HGF 2.5, 5, 10, 20, 40, 50*, 75, 
80, 100 ng/ml 
Down 
L-NMA 100, 250 µM No 
PMA 10 ng/ml No 
LPS (B5 and B8) 0.1, 1, 10, 100*, 1000 
2500 ng/ml 
Up 







